Latest Advances in Lung Cancer Research

A 65-year-old surfer overcame early-stage EGFR-positive lung cancer using stereotactic body radiation therapy (SBRT), a precise, non-surgical treatment that spared his lung capacity.

The FDA has approved a new drug called Datroway (datopotamab deruxtecan) for patients with EGFR-positive non-small cell lung cancer (NSCLC) who have already tried targeted therapy and chemotherapy. This approval marks an important step forward in lung cancer treatment.

Clinical cancer informatics research applying computational methods or digital health technologies to improve cancer care and patient outcomes.

Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.

Study shows 70 Gy radiation doses for lung cancer don’t increase pneumonitis risk and may improve survival compared to lower doses.

Dr. Ramalingam emphasizes community oncologists must prioritize molecular testing and lung cancer screening to improve patient access to treatments.

Research develops hypoxic gene expression signatures to predict which muscle-invasive bladder cancer patients will respond to hypoxia-modifying therapies.

A new study shows adding immunotherapy to chemotherapy before lung cancer surgery significantly improves five-year survival rates in patients.

FDA fast-tracks ZL-1310, a promising targeted therapy showing 74% response rate in advanced small cell lung cancer patients with limited treatment options.

AbbVie’s Emrelis, an FDA-approved drug, targets c-Met proteins in NSCLC for effective cancer treatment, marking significant advancements in antibody-drug conjugates (ADCs).

Study reveals lung cancer itself causes brain structural changes and cognitive impairment in patients before receiving any chemotherapy treatment.

COCOON study shows simple preventive skin care regimen reduces severe skin reactions by 50% in lung cancer patients receiving amivantamab-lazertinib treatment.